Olanzapine-induced metabolic syndrome is partially mediated by oxytocinergic system dysfunction in female Sprague-Dawley rats
PLOS One · 2025
DOI: 10.1371/journal.pone.0334966 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Elsie D Oduor und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Anatomy and Medical Physiology, University of Nairobi, Nairobi, Kenya. Hauptthemen laut MEDLINE: Oxytocin, Metabolic Syndrome, Antipsychotic Agents, Benzodiazepines. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Olanzapine (OLZ), a second-generation antipsychotic, is associated with the development of metabolic syndrome with unclear underlying pathophysiologic mechanisms. Oxytocin (OT) influences feeding, lipid, and glucose metabolism. This study investigates whether dysfunction in the oxytocinergic system contributes to the development of olanzapine-induced metabolic syndrome.
Methods
Twenty five (25) female Sprague-Dawley rats were housed under standard conditions and studied over 12 weeks. During the first 6-week induction phase, rats were randomized into 3 groups: normal control (vehicle treatment; normal saline; n = 5), low dose (4 mg/kg olanzapine [OLZ]; n = 5), and high dose (8 mg/kg OLZ; n = 15). In the last 6-week treatment phase, the high dose group was re-randomized into 3 groups: negative control (8 mg/kg OLZ; n = 5), positive control (8 mg/kg OLZ + 500 mg/kg metformin; n = 5), and test group (8 mg/kg OLZ + 1 mg/kg oxytocin [OT]; n = 5). The normal control and low dose groups continued unchanged. Body weight, food intake, glucose levels, OGTT, lipid profile, visceral fat, hepatic index, hepatic triglycerides, and steatosis were assessed.
Results
At induction end, high-dose OLZ increased food intake (179 ± 5 g), body weight (239 ± 3 g), blood glucose (7.8 ± 0.3 mmol/L), and impaired glucose tolerance (846 ± 25 mmol/L·min) compared to controls (p < 0.0001). Post-treatment, the test group displayed reduced food intake (163 ± 2 g vs. 197 ± 6 g), body weight (297 ± 2 g vs. 376 ± 6 g), blood glucose (5.8 ± 0.3 mmol/L vs. 9.8 ± 0.2 mmol/L), and improved glucose tolerance (711 ± 14 vs. 853 ± 9 mmol/L·min) compared to negative controls (p < 0.0001). LDL-C, total cholesterol, serum and hepatic triglycerides, visceral adipose, and hepatic mass and steatosis were also significantly decreased in the test group compared to negative control group (p < 0.01).
Conclusion
OLZ-induced metabolic abnormalities were mitigated by oxytocin, indicating that the oxytocinergic system hypofunction may be implicated in its pathophysiology. These results highlight OT’s therapeutic potential and call for further clinical research to explore its role in the management of antipsychotic-induced metabolic syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Human Anatomy and Medical Physiology, University of Nairobi, Nairobi, Kenya.
- School of Health Sciences, Dedan Kimathi University of Technology, Nyeri, Kenya.
ORCID-Profile: Elsie D Oduor
Zitieren
APA
Oduor, E. D., Mwangi, P. W., Chege, B. M., Olago, S. F., & Bukachi, F. (2025). Olanzapine-induced metabolic syndrome is partially mediated by oxytocinergic system dysfunction in female Sprague-Dawley rats. PLOS One. https://doi.org/10.1371/journal.pone.0334966
Vancouver
Oduor ED, Mwangi PW, Chege BM, Olago SF, Bukachi F. Olanzapine-induced metabolic syndrome is partially mediated by oxytocinergic system dysfunction in female Sprague-Dawley rats. PLOS One. 2025. doi:10.1371/journal.pone.0334966
BibTeX
@article{Oduor2025,
author = {Oduor, Elsie D and Mwangi, Peter W and Chege, Boniface M and Olago, Sharon F and Bukachi, Frederick},
title = {Olanzapine-induced metabolic syndrome is partially mediated by oxytocinergic system dysfunction in female Sprague-Dawley rats},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0334966}
}
EUVIMED